Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 86, Issue 6, Pages 672-677Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2009.201
Keywords
-
Categories
Funding
- Sackler Foundation
- National Alliance for Research on Schizophrenia and Depression
- National Institute of Mental Health (NIMH)
Ask authors/readers for more resources
Selective serotonin reuptake inhibitor (SSRI) antidepressants are frequently used in the management of antenatal maternal mood disturbances. SSRIs readily cross the placenta and increase central serotonergic tone in the fetus. Given serotonin's key neurodevelopmental role, such prenatal exposure raises concerns about its impact on child development. Preclinical studies report enduring molecular, physiological, and behavioral consequences of developmental SSRI exposure. In humans, sustained developmental outcomes remain largely unstudied, and distinguishing between the effects of prenatal SSRI exposure and the impact of maternal mental illness remains a key challenge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available